CD274 and non-small cell lung carcinoma: This meta-analysis systematically evaluated the efficacy and safety of PD-1/PD-L1 inhibitors combined with nab-paclitaxel and platinum-based chemotherapy in 1,998 patients with NSCLC across four RCTs, including both advanced and resectable disease settings.